Abstract
The strategy in the treatment of metastatic renal cell carcinoma (MRCC) is based on prognostic factors for survival. General performance status, delay from the diagnosis of primary tumor to occurrence of metastases, number of metastatic sites or site of metastases (lung, liver) and biological changes such as hemoglobin value, calcium value, and sedimentation rate are reported as the most predictive factors for survival. The first line of treatment in MRCC is immunotherapy for the majority of patients. Disagreement remains regarding the choice of immunotherapy: interleukin-2 (IL-2) and/or interferon alpha; and the mode of administration of IL-2: intravenous or subcutaneous route. Major therapeutic changes are coming with new drugs directed against new targets. Bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF) has been approved in second-line treatment. Other compounds are under investigation such as drugs targeting the EGF and Ras pathways.
Keywords: biphosphonates, immunotherapy, anti-angiogenic therapy, metastatic sites, nephrectomy, fluorouracile, cardiac toxicity, antitumoral activity, interferon (ifn)
Current Cancer Therapy Reviews
Title: Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma
Volume: 1 Issue: 2
Author(s): Alain Ravaud, Marie-Sarah Dilhuydy, Aimery Huchet, Stephane Pedeboscq and Jean-Philippe Maire
Affiliation:
Keywords: biphosphonates, immunotherapy, anti-angiogenic therapy, metastatic sites, nephrectomy, fluorouracile, cardiac toxicity, antitumoral activity, interferon (ifn)
Abstract: The strategy in the treatment of metastatic renal cell carcinoma (MRCC) is based on prognostic factors for survival. General performance status, delay from the diagnosis of primary tumor to occurrence of metastases, number of metastatic sites or site of metastases (lung, liver) and biological changes such as hemoglobin value, calcium value, and sedimentation rate are reported as the most predictive factors for survival. The first line of treatment in MRCC is immunotherapy for the majority of patients. Disagreement remains regarding the choice of immunotherapy: interleukin-2 (IL-2) and/or interferon alpha; and the mode of administration of IL-2: intravenous or subcutaneous route. Major therapeutic changes are coming with new drugs directed against new targets. Bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF) has been approved in second-line treatment. Other compounds are under investigation such as drugs targeting the EGF and Ras pathways.
Export Options
About this article
Cite this article as:
Ravaud Alain, Dilhuydy Marie-Sarah, Huchet Aimery, Pedeboscq Stephane and Maire Jean-Philippe, Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021709
DOI https://dx.doi.org/10.2174/1573394054021709 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Impact of Inhibitors of the Renin-Angiotensin-Aldosterone System on Liver Fibrosis and Portal Hypertension
Current Medicinal Chemistry Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Anticancer Potential of Thiazole Derivatives: A Retrospective Review
Mini-Reviews in Medicinal Chemistry Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Current Drug Targets Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies
Current Pharmaceutical Biotechnology Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry